JP2004525855A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004525855A5 JP2004525855A5 JP2001523012A JP2001523012A JP2004525855A5 JP 2004525855 A5 JP2004525855 A5 JP 2004525855A5 JP 2001523012 A JP2001523012 A JP 2001523012A JP 2001523012 A JP2001523012 A JP 2001523012A JP 2004525855 A5 JP2004525855 A5 JP 2004525855A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- sequence
- protein
- strain
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39787399A | 1999-09-17 | 1999-09-17 | |
| US09/397,873 | 1999-09-17 | ||
| PCT/US2000/025510 WO2001019380A2 (en) | 1999-09-17 | 2000-09-18 | Oncolytic virus |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004525855A JP2004525855A (ja) | 2004-08-26 |
| JP2004525855A5 true JP2004525855A5 (cg-RX-API-DMAC7.html) | 2007-11-15 |
| JP5060694B2 JP5060694B2 (ja) | 2012-10-31 |
Family
ID=23573018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001523012A Expired - Fee Related JP5060694B2 (ja) | 1999-09-17 | 2000-09-18 | 腫瘍崩壊性ウイルス |
Country Status (13)
| Country | Link |
|---|---|
| EP (2) | EP1716858B9 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5060694B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN1289098C (cg-RX-API-DMAC7.html) |
| AT (2) | ATE319460T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU782402B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2386920C (cg-RX-API-DMAC7.html) |
| DE (2) | DE60026554T2 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2260057T3 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1044708B (cg-RX-API-DMAC7.html) |
| IL (2) | IL148621A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA02002772A (cg-RX-API-DMAC7.html) |
| NZ (4) | NZ523805A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2001019380A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ425699A0 (en) | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
| US8491884B2 (en) | 2000-05-03 | 2013-07-23 | Oncolytics Biotech Inc. | Virus clearance of neoplastic cells from mixed cellular compositions |
| US7306902B2 (en) * | 2002-06-28 | 2007-12-11 | Oncolyties Biotech Inc. | Oncolytic viruses as phenotyping agents for neoplasms |
| WO2002000233A2 (en) | 2000-06-26 | 2002-01-03 | Wellstat Biologics Corporation | Purging of cells using viruses |
| NZ527687A (en) | 2001-05-11 | 2005-10-28 | Wellstat Biolog Corp Formerly | Preferential binding of an oncolytic virus such as Newcastle Disease Virus (NDV) to leukocytes compared with erythrocytes used as a therapy for cancer |
| AU2008201293B2 (en) * | 2001-07-11 | 2011-08-18 | University Of Miami | Recombinant VSV for the treatment of tumor cells |
| CA2452517A1 (en) * | 2001-07-11 | 2003-01-23 | University Of Miami | Recombinant vsv for the treatment of tumor cells |
| JP2004099584A (ja) | 2002-05-02 | 2004-04-02 | Keio Gijuku | Hsvを用いた抗腫瘍剤 |
| AU2002953436A0 (en) | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
| US7731974B2 (en) * | 2003-03-27 | 2010-06-08 | Ottawa Hospital Research Institute | Mutant vesicular stomatitis viruses and uses thereof |
| ATE539162T1 (de) | 2003-03-27 | 2012-01-15 | Ottawa Hospital Res Inst | Mutierte viren der vesikulären stomatitis und deren verwendung |
| CA2568772A1 (en) | 2004-06-01 | 2005-12-15 | San Diego State University Foundation | Expression system based on recombinant vesicular stomatitis virus synthesizing t7 rna polymerase |
| KR101295733B1 (ko) | 2004-08-20 | 2013-08-13 | 비랄리틱스 리미티드 | 혈액암의 치료방법 및 조성물 |
| ZA200702269B (en) * | 2004-08-20 | 2008-09-25 | Viralytics Ltd | Methods and compositions for treatment of hematologic cancers |
| US10668119B2 (en) | 2005-08-01 | 2020-06-02 | Virocure, Inc. | Attenuated reovirus |
| WO2007099401A2 (en) | 2005-08-01 | 2007-09-07 | University Technologies International, Inc. | Oncolytic attenuated reoviruses for treatment of proliferative disorders |
| WO2009016433A2 (en) * | 2006-09-15 | 2009-02-05 | Ottawa Health Research Institute | Oncolytic rhabdovirus |
| US10369171B2 (en) | 2007-03-13 | 2019-08-06 | Virocure, Inc. | Attenuated reoviruses for selection of cell populations |
| WO2009082664A2 (en) * | 2007-12-21 | 2009-07-02 | Wyeth | Genetically modified attenuated vesicular stomatitis virus, compositions and methods of use thereof |
| US10603351B2 (en) | 2008-08-21 | 2020-03-31 | Turnstone Limited Partnership | Engineered synergistic oncolytic viral symbiosis |
| DE102008050860A1 (de) * | 2008-10-08 | 2010-04-15 | Dorothee Von Laer | LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virenproduzentenzellen zur Therapie von Tumoren |
| WO2010105347A1 (en) | 2009-03-16 | 2010-09-23 | Mcmaster University | Vaccination methods |
| WO2011070440A2 (en) | 2009-12-10 | 2011-06-16 | Ottawa Hospital Research Institute | Oncolytic rhabdovirus |
| US9951117B2 (en) | 2010-09-02 | 2018-04-24 | Mayo Foundation For Medical Education And Research | Vesicular stomatitis viruses |
| JP5944901B2 (ja) * | 2010-09-02 | 2016-07-05 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | 水疱性口内炎ウイルス |
| EP2718427B1 (en) | 2011-06-08 | 2017-01-11 | Children's Hospital of Eastern Ontario Research Institute Inc. | Compositions for glioblastoma treatment |
| WO2013050048A2 (en) | 2011-10-07 | 2013-04-11 | Skau Aps | Identification and attenuation of the immunosuppressive domains in fusion proteins of enveloped rna viruses |
| RU2019107976A (ru) | 2013-02-21 | 2019-08-23 | Тёрнстоун Лимитед Партнершип | Композиция вакцины |
| EP3906931A3 (en) * | 2013-04-10 | 2022-02-23 | iSD Immunotech ApS | Use of immune suppressive domains as medicaments |
| US10066214B2 (en) | 2013-06-14 | 2018-09-04 | Turnstone Limited Partnership | Compositions and methods for enhancing virus replication |
| EP2826856B9 (en) * | 2013-07-16 | 2016-05-04 | Sia Latima | Genetically stable oncolytic RNA virus, method of manufacturing and use thereof |
| US11015229B2 (en) | 2014-07-21 | 2021-05-25 | Novellusdx Ltd. | Methods and systems for determining oncogenic index of patient specific mutations |
| CN105233285B (zh) * | 2015-09-06 | 2018-10-12 | 广州威溶特医药科技有限公司 | Epac直接或间接激动剂与溶瘤病毒的联合应用 |
| US12351812B2 (en) | 2017-05-19 | 2025-07-08 | Georgia State University Research Foundation, Inc. | Recombinant oncolytic virus |
| US10610583B2 (en) | 2017-08-31 | 2020-04-07 | Regents Of The University Of Minnesota | Methods and compositions for treating glioma and medulloblastoma brain tumors using the zika virus |
| PT3684786T (pt) | 2017-09-22 | 2024-10-30 | Centre Nat Rech Scient | Glicoproteína mutante do vírus da estomatite vesicular |
| CN110499297B (zh) * | 2019-08-29 | 2021-07-09 | 上海市公共卫生临床中心 | 一种新型溶瘤病毒及其制备方法和应用 |
| US20240318147A1 (en) * | 2020-08-14 | 2024-09-26 | Revoimmune Therapeutics Inc. | Recombinant oncolytic virus, and construction method therefor and use thereof |
| US20240299540A1 (en) | 2021-02-05 | 2024-09-12 | Iovance Biotherapeutics, Inc. | Adjuvant therapy for cancer |
| CA3212006A1 (en) | 2021-02-26 | 2022-09-01 | Kelonia Therapeutics, Inc. | Lymphocyte targeted lentiviral vectors |
| EP4784626A1 (en) | 2023-09-25 | 2026-08-05 | Kelonia Therapeutics, Inc. | Antigen binding polypeptides |
| IL327310A (en) | 2023-09-25 | 2026-05-01 | Kelonia Therapeutics Inc | Cancer treatment vehicles |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1118403B (de) | 1960-01-27 | 1961-11-30 | Hoechst Ag | Verfahren zur Gewinnung von antitumorwirksamen Sporen |
| GB1069144A (en) | 1963-07-10 | 1967-05-17 | Merck & Co Inc | Method for the treatment of malignant tumors |
| US4806347A (en) | 1985-12-11 | 1989-02-21 | Schering Corporation | Interferon combinations |
| ES2188593T3 (es) * | 1992-03-24 | 2003-07-01 | United Cancer Res Inst | Vacuna que contiene un virus vivo. |
| GB9415320D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | Cancer treatment |
| US7153510B1 (en) * | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
| EP1314430A1 (en) | 1996-01-25 | 2003-05-28 | The University Court Of The University Of Glasgow | Treatment of non-neuronal cancer using HSV mutant |
| DE69837764T2 (de) * | 1997-07-11 | 2008-01-31 | Yale University, New Haven | Rhabdovirus mit gentechnisch veränderter hülle |
| EP1905304A3 (en) * | 1997-10-09 | 2008-08-13 | Wellstat Biologics Corporation | Treatment of neoplasms with viruses |
| IL136905A0 (en) * | 1997-12-22 | 2001-06-14 | Univ Tennessee Res Corp | Recombinant rhabdovirus containing a heterologous fusion protein |
| EP1061806A4 (en) * | 1998-03-12 | 2001-09-12 | Univ Pennsylvania | PRODUCTIVE CELLS FOR REPLICATION-SELECTIVE VIRUSES FOR TREATING Vicious DISEASES |
| SK288544B6 (sk) * | 1998-06-12 | 2018-03-05 | Mount Sinai School Of Medicine | Geneticky skonštruovaný oslabený chimérny vírus chrípky, vakcinačný prostriedok a farmaceutický prostriedok s jeho obsahom a ich použitie |
| CN1477964A (zh) * | 1999-04-15 | 2004-02-25 | 应用病毒治疗肿瘤 |
-
2000
- 2000-09-18 AU AU75882/00A patent/AU782402B2/en not_active Ceased
- 2000-09-18 MX MXPA02002772A patent/MXPA02002772A/es active IP Right Grant
- 2000-09-18 AT AT00965106T patent/ATE319460T1/de active
- 2000-09-18 DE DE60026554T patent/DE60026554T2/de not_active Expired - Lifetime
- 2000-09-18 HK HK02105578.7A patent/HK1044708B/en not_active IP Right Cessation
- 2000-09-18 NZ NZ523805A patent/NZ523805A/en not_active IP Right Cessation
- 2000-09-18 DE DE60041210T patent/DE60041210D1/de not_active Expired - Lifetime
- 2000-09-18 CA CA2386920A patent/CA2386920C/en not_active Expired - Fee Related
- 2000-09-18 ES ES00965106T patent/ES2260057T3/es not_active Expired - Lifetime
- 2000-09-18 JP JP2001523012A patent/JP5060694B2/ja not_active Expired - Fee Related
- 2000-09-18 EP EP05025974A patent/EP1716858B9/en not_active Expired - Lifetime
- 2000-09-18 NZ NZ534306A patent/NZ534306A/en not_active IP Right Cessation
- 2000-09-18 ES ES05025974T patent/ES2320239T3/es not_active Expired - Lifetime
- 2000-09-18 EP EP00965106A patent/EP1218019B1/en not_active Expired - Lifetime
- 2000-09-18 NZ NZ534307A patent/NZ534307A/en not_active IP Right Cessation
- 2000-09-18 IL IL14862100A patent/IL148621A0/xx unknown
- 2000-09-18 AT AT05025974T patent/ATE418341T1/de active
- 2000-09-18 WO PCT/US2000/025510 patent/WO2001019380A2/en not_active Ceased
- 2000-09-18 CN CNB008158983A patent/CN1289098C/zh not_active Expired - Fee Related
- 2000-09-18 NZ NZ517573A patent/NZ517573A/en not_active IP Right Cessation
-
2002
- 2002-03-11 IL IL148621A patent/IL148621A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL148621A (en) | Use of a virus for the manufacture of a medicament for reducing the viability of tumor cells and some isolated nucleic acid sequences | |
| Fu et al. | Engineering cytokines for cancer immunotherapy: a systematic review | |
| AU2024203377B2 (en) | Altering inflammatory states of immune cells in vivo by modulating cellular activation states | |
| Vigil et al. | Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus | |
| JP2024503623A5 (cg-RX-API-DMAC7.html) | ||
| Shinozaki et al. | Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus | |
| ES2296750T3 (es) | Forma mutada de la arginina deiminasa. | |
| DK1317537T3 (da) | Sammensætninger og fremgangsmåder med G-CSF analoger | |
| KR20120049185A (ko) | 암 치료용 암 용해성 아데노바이러스 | |
| WO2003077834A3 (en) | Central airway administration for systemic delivery of therapeutics | |
| CA2095836A1 (en) | Cytokine immunoconjugates | |
| WO2004004798A3 (en) | Central airway administration for systemic delivery of therapeutics | |
| JP2024534387A5 (cg-RX-API-DMAC7.html) | ||
| Sakurai et al. | Therapeutic effect of intravenous delivery of lipoplexes containing the interferon-β gene and poly I: poly C in a murine lung metastasis model | |
| JP2021525517A5 (cg-RX-API-DMAC7.html) | ||
| Sato et al. | Enhancement of anti-tumor activity of recombinant interleukin-2 (rIL-2) by immunocomplexing with a monoclonal antibody against rIL-2 | |
| JP2005225888A5 (cg-RX-API-DMAC7.html) | ||
| Kim et al. | Interferon alpha and beta receptor 1 knockout in human embryonic kidney 293 cells enhances the production efficiency of proteins or adenoviral vectors related to type I interferons | |
| JP2025141963A (ja) | ウイルスを含む抗癌関連非腫瘍細胞剤 | |
| JP2007516214A5 (cg-RX-API-DMAC7.html) | ||
| Lan et al. | Inflammatory Cytokines in Cancer: Comprehensive Understanding and Clinical Progress in Gene Therapy. Cells 2021, 10, 100 | |
| CN117660368B (zh) | 表达趋化因子ccl19的重组溶瘤流感病毒及应用 | |
| Nishimura et al. | Antitumor and antimetastatic activities of human recombinant interferon alpha A/D | |
| US20070237743A1 (en) | Combination therapies using low-toxicity, long-circulating human interferon-alpha analogs | |
| US7662370B2 (en) | Low-toxicity, long-circulating human interferon-alpha PEGylated mutants |